Prelude Therapeutics (PRLD) Non Operating Income (2019 - 2026)

Prelude Therapeutics has disclosed Non Operating Income across 8 years of filings, most recently posting $3.8 million for Q1 2026.

• Non Operating Income for Q1 2026 came in at $3.8 million, up 50.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.3 million (down 47.83% YoY), and the FY2025 annual result was $5.1 million, down 59.59% from the prior year.
• Non Operating Income came in at $3.8 million for Q1 2026 at Prelude Therapeutics, up from $891000.0 in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $5.1 million in Q4 2024 to a low of $448000.0 in Q3 2022.
• The 5-year median for Non Operating Income is $2.1 million (2024), against an average of $2.3 million.
• Across the five-year window, Non Operating Income jumped 2723.81% in 2022 and sank 82.53% in 2025, its largest moves.
• Prelude Therapeutics' Non Operating Income stood at $4.7 million in 2022, then declined by 9.27% to $4.3 million in 2023, then advanced by 18.49% to $5.1 million in 2024, then tumbled by 82.53% to $891000.0 in 2025, then jumped by 325.59% to $3.8 million in 2026.
• The last three Non Operating Income figures came in at $3.8 million (Q1 2026), $891000.0 (Q4 2025), and $693000.0 (Q3 2025), per Business Quant data.